Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and
marketing innovative surgical solutions for peripheral nerve
injuries, is pleased to announce today the appointment of Mrs.
Kathy Weiler to its Board of Directors, effective December 20,
2023. Weiler, a senior executive with 20+ years of experience and
proven track record in driving strategic commercial initiatives,
will serve on the Board’s Governance, Nominating and Sustainability
Committee, and the Quality, Compliance, and Portfolio Management
Committee.
“I am happy to welcome Kathy to the Board as
Axogen is approaching an exciting inflection point in its journey,”
commented Karen Zaderej, chairman, CEO, and president. “We look
forward to working closely with Kathy and leveraging her extensive
commercial experience to support Axogen’s patient activation and
commercial execution, as we drive toward being cash flow
positive.”
Weiler is the Executive Vice President, Chief
Commercial and Growth Officer at Amwell (NYSE: AMWL). Weiler
oversees the company’s growth strategy, driving strategic
initiatives and leading business development, sales and account
management, commercial enablement, marketing, and strategic and
channel partnership teams. Prior to Amwell, Weiler served as Chief
Consumer Officer at Optum, where she led consumerism across the
enterprise. Preceding that, she was Chief Consumer Strategy Officer
at UnitedHealth Group and the Chief Marketing and Experience
Officer of Optum Health, leading marketing efforts for Optum Care
and Optum’s Population Health Solutions, Complex Care Management,
Medical Benefits Management, Behavioral Health, Prevention and
Financial Services businesses. Weiler also served as Chief
Marketing and Product Officer at Blue Cross and Blue Shield of
Massachusetts, where she drove strategic growth and retention
business objectives. Weiler spent her earlier career with multiple
financial services organizations. She was Chief Marketing Officer
of Fidelity Investments FAS business and held senior marketing
leadership roles at BNY Mellon/Pershing and The Hartford. Weiler
holds a B.A. from Bowdoin College and an M.A. in International
Economics and Finance from Brandeis University.
“I am impressed by Axogen’s unique products that
restore quality of life for patients with nerve injuries,” said
Weiler. “I am excited to join the Board and contribute to the
Company’s strategic path, and it’s commercial success.”
About Axogen
Axogen (AXGN) is the leading Company focused
specifically on the science, development, and commercialization of
technologies for peripheral nerve regeneration and repair. Axogen
employees are passionate about helping to restore peripheral nerve
function and quality of life to patients with physical damage or
transection to peripheral nerves by providing innovative,
clinically proven, and economically effective repair solutions for
surgeons and health care providers. Peripheral nerves provide the
pathways for both motor and sensory signals throughout the body.
Every day, people suffer traumatic injuries or undergo surgical
procedures that impact the function of their peripheral nerves.
Physical damage to a peripheral nerve, or the inability to properly
reconnect peripheral nerves, can result in the loss of muscle or
organ function, the loss of sensory feeling, or the initiation of
pain.
Axogen's platform for peripheral nerve repair
features a comprehensive portfolio of products that are used across
two primary application categories: scheduled, non-trauma
procedures and emergent trauma procedures. Scheduled procedures are
generally characterized as those where a patient is seeking relief
from conditions caused by a nerve defect or surgical procedure.
These procedures include providing sensation for women seeking
breast reconstruction following a mastectomy, nerve reconstruction
following the surgical removal of painful neuromas, oral and
maxillofacial procedures, and nerve decompression. Emergent
procedures are generally characterized as procedures resulting from
injuries that initially present in an ER. These procedures are
typically referred to and completed by a specialist either
immediately or within a few days following the initial injury.
Axogen’s product portfolio includes Avance®
Nerve Graft, a biologically active off-the-shelf processed human
nerve allograft for bridging severed peripheral nerves without the
comorbidities associated with a second surgical site; Axoguard
Nerve Connector®, a porcine submucosa ECM coaptation aid for
tensionless repair of severed peripheral nerves; Axoguard Nerve
Protector®, a porcine submucosa ECM product used to wrap and
protect damaged peripheral nerves and reinforce the nerve
reconstruction while preventing soft tissue attachments; Axoguard
HA+ Nerve Protector™, a porcine submucosa ECM base layer coated
with a proprietary hyaluronate-alginate gel, a next-generation
technology designed to provide short- and long-term protection for
peripheral nerve injuries; and Axoguard Nerve Cap®, a porcine
submucosa ECM product used to protect a peripheral nerve end and
separate the nerve from the surrounding environment to reduce the
development of symptomatic or painful neuroma. The Axogen portfolio
of products is available in the United States, Canada, Germany, the
United Kingdom, Spain, South Korea, and several other
countries.
Cautionary Statements Concerning
Forward-Looking Statements
This press release contains “forward-looking”
statements as defined in the Private Securities Litigation Reform
Act of 1995. These statements are based on management's current
expectations or predictions of future conditions, events, or
results based on various assumptions and management's estimates of
trends and economic factors in the markets in which we are active,
as well as our business plans. Words such as “expects,”
“anticipates,” “intends,” “plans,” “believes,” “seeks,”
“estimates,” “projects,” “forecasts,” “continue,” “may,” “should,”
“will,” “goals,” and variations of such words and similar
expressions are intended to identify such forward-looking
statements. Forward looking statements include the statement that
Axogen is approaching an exciting inflection point in its journey
and the statement about leveraging Mrs. Weiler’s extensive
commercial experience to support Axogen’s patient activation and
commercial execution as we drive toward being cash flow positive.
Actual results or events could differ materially from those
described in any forward-looking statements as a result of various
factors, including, without limitation, the continued impact of
COVID-19, global supply chain issues, record inflation, hospital
staffing issues, product development, product potential, expected
clinical enrollment timing and outcomes, regulatory process and
approvals, processing facility transition timing and expense,
financial performance, sales growth, surgeon and product adoption,
market awareness of our products, data validation, our visibility
at and sponsorship of conferences and educational events, global
business disruption caused by Russia’s invasion of Ukraine and
related sanctions, as well as those risk factors described under
Part I, Item 1A., “Risk Factors,” of our Annual Report on Form 10-K
for the most recently ended fiscal year and Part II, Item 1A.,
“Risk Factors,” for our Quarterly Report on Form 10-Q for the most
recently ended fiscal quarter. Forward-looking statements are not a
guarantee of future performance, and actual results may differ
materially from those projected. The forward-looking statements are
representative only as of the date they are made and, except as
required by applicable law, we assume no responsibility to publicly
update or revise any forward-looking statements.
Contact:Axogen, Inc.Harold D.
Tamayo, Vice President, Finance and Investor
Relationshtamayo@axogeninc.com
Axogen (NASDAQ:AXGN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Axogen (NASDAQ:AXGN)
Historical Stock Chart
From Apr 2023 to Apr 2024